3Wong SN, Lok AS. Update on viral hepatitis: 2005 [ J ]. Curr Opin Gastroenterol,2006,22(3 ) :241-247.
4Lok AS,The maze of treatments for hepatitis B [ J ]. N Kngl J Med, 2005,352(26) :2743-2746.
5Lai CL, Rosmawati M, Lao J, et al, Enteavifis supenior lamivudine in reducing hepatitis B infection [ J ]. Gastronterology, 2002,123 ( 6 ) : 1831-1838.
6Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-inter- feron treatment in Patients with hepatitis B e antigen-positive chronic hepatitis B : a meta analysis Ann Intern Med, 1993,119:312-323.
7Fattovich G, Farci P, Rugge M, et al. A randomized controlled tri- M of lympholastoid interferon-alpha in Patients with chronic hepatitis B lacking HBeAg Hepatology, 1992,15:584-589.
8Davis GL. Hepatitis B: diagnosis and treatment. South Med J, 1997,90(9) :866-871.
9Schiff E, Cianeiara J, Karayaiein S, et al. The international lami- vudine investigator group, Durable HbeAg and HbsAg serocon ver- sion after lamivudine for chronic hepatitis B. J Hepatol, 2003, 32:99.
10Marion P, H.W. Harm, P. Martin, et al. AdefoVir dipiVoxil (ADV) alone and in combination with lamiVudine (LAM) suppress YMDD mutant hepatitis B Virus replication :48 week preliminary a- nalysis. Hepatolo, 2002,36:374A.
